Top 5 Stock Picks of Samuel Isaly’s OrbiMed Advisors

3. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

OrbiMed Advisors Stake Value: $285,938,000
Percentage of OrbiMed Advisors’ 13F Portfolio: 3.14%
Number of Hedge Fund Holders: 60

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) is a biopharmaceutical business specializing in rare and rheumatic illness research, development, and commercialization. In December, Wells Fargo analyst Derek Archila initiated coverage of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP), rating the stock as “Overweight” and keeping a price target of $137.

According to the 13F filings for the third quarter of 2021, OrbiMed Advisors holds 2.61 million shares of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP), amounting to more than $285.94 million, representing 3.14% of the fund’s portfolio value. The hedge fund reduced its stake in the company by 11% in the third quarter of 2021.

Overall, hedge funds are loading up on Horizon Therapeutics Public Limited Company (NASDAQ:HZNP), as 60 out of the 867 funds tracked by Insider Monkey held stakes in the biopharmaceutical company in the third quarter, compared to 56 funds a quarter earlier.

Carillon Tower Advisers, an investment management firm, in its first-quarter 2021 investor letter, mentioned Horizon Therapeutics Public Limited Company (NASDAQ:HZNP). Here is what the fund said:

“Horizon Therapeutics is a biopharmaceutical company whose primary focus is research, development, and marketing of late-stage pharmaceutical products. After experiencing some unfortunate manufacturing hiccups in the later stages of 2020 for its key product Tepezza, which is used in the treatment of thyroid eye disease, the company recently received positive news that should relieve their supply issues going forward. With manufacturing of Tepezza back online after being forced to halt due to Operation Warp Speed’s COVID-19 vaccine production orders, Horizon expects patient treatments to resume in mid-April.”